Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen de las Nieves (23)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

2022

  1. RICORS2040: The need for collaborative research in chronic kidney disease

    Clinical Kidney Journal, Vol. 15, Núm. 3, pp. 372-387

2019

  1. A composite indicator to assess the quality of care in the management of patients with rheumatoid arthritis in outpatient rheumatology clinics

    Reumatologia Clinica, Vol. 15, Núm. 3, pp. 156-164

  2. New anti-epileptic drugs in Paediatrics

    Anales de Pediatria, Vol. 91, Núm. 6, pp. 415.e1-415.e10

  3. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring in clinical practice: the spanish cohort of the COMORA study

    Reumatologia Clinica, Vol. 15, Núm. 2, pp. 102-108

2017

  1. A combined large-scale meta-Analysis identifies COG6 as a novel shared risk locus for rheumatoid arthritis and systemic lupus erythematosus

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 1, pp. 286-294

  2. Very early and early systemic sclerosis in the Spanish scleroderma Registry (RESCLE) cohort

    Autoimmunity Reviews, Vol. 16, Núm. 8, pp. 796-802

2016

  1. Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies

    Seminars in Arthritis and Rheumatism, Vol. 45, Núm. 4, pp. 391-399

  2. Off-label use of rituximab for systemic lupus erythematosus in Europe

    Lupus Science and Medicine, Vol. 3, Núm. 1

2015

  1. Registry of the Spanish network for systemic sclerosis: Survival, prognostic factors, and causes of death

    Medicine (United States), Vol. 94, Núm. 43

  2. Variability in the prescription of non-biologic disease-modifying antirheumatic drugs for the treatment of spondyloarthritis in Spain

    Seminars in Arthritis and Rheumatism, Vol. 44, Núm. 6, pp. 633-640

2014

  1. Analysis of ancestral and functionally relevant CD variants in systemic lupus erythematosus patients

    PLoS ONE, Vol. 9, Núm. 11

2013

  1. Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis

    European Journal of Paediatric Neurology, Vol. 17, Núm. 1, pp. 50-54

2012

  1. The undiagnosed cases of Clostridium difficile infection in a whole nation: Where is the problem?

    Clinical Microbiology and Infection, Vol. 18, Núm. 7

2011

  1. Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label

    Arthritis Research and Therapy, Vol. 13, Núm. 4

2010

  1. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases

    Clinical and Experimental Rheumatology, Vol. 28, Núm. 4, pp. 468-476

2009

  1. Investigation of TLR5 and TLR7 as candidate genes for susceptibility to systemic lupus erythematosus

    Clinical and Experimental Rheumatology

  2. No evidence for genetic association of interferon regulatory factor 3 in systemic lupus erythematosus

    Lupus, Vol. 18, Núm. 3, pp. 230-234

  3. STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk

    Annals of the Rheumatic Diseases, Vol. 68, Núm. 11, pp. 1746-1753

2008

  1. Staphylococcus spp. en España: Situación actual y evolución de la resistencia a antimicrobianos (1986-2006)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 26, Núm. 5, pp. 269-277